Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.52M | 6.24M | 2.83M | 6.42M | 1.48M | 0.00 | Gross Profit |
5.17M | 5.82M | 2.47M | 6.27M | -544.00K | -1.98M | EBIT |
-117.20M | -101.86M | -48.17M | -29.70M | -13.09M | -78.70M | EBITDA |
-117.00M | -101.86M | -48.17M | -29.56M | -13.09M | -72.96M | Net Income Common Stockholders |
-100.73M | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
263.23M | 275.24M | 173.72M | 75.49M | 7.64M | 148.84M | Total Assets |
348.58M | 374.01M | 179.41M | 83.11M | 9.45M | 161.62M | Total Debt |
1.40M | 1.49M | 585.00K | 788.00K | 0.00 | 0.00 | Net Debt |
-8.72M | -21.30M | -131.74M | -14.58M | -7.64M | -58.15M | Total Liabilities |
19.97M | 21.53M | 10.54M | 127.48M | 26.70M | 17.71M | Stockholders Equity |
328.61M | 352.48M | 168.87M | -44.37M | -17.25M | 143.91M |
Cash Flow | Free Cash Flow | ||||
-78.10M | -78.28M | -36.97M | -29.21M | -9.94M | -64.42M | Operating Cash Flow |
-78.19M | -78.18M | -36.86M | -29.07M | -9.90M | -64.02M | Investing Cash Flow |
-316.22M | -286.81M | 20.25M | -59.82M | -33.00K | -10.63M | Financing Cash Flow |
203.88M | 255.62M | 133.57M | 96.68M | 14.91M | 67.74M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $718.21M | ― | -6.33% | ― | 23.92% | -27.69% | |
55 Neutral | $639.97M | ― | -55.12% | ― | ― | -60.26% | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
48 Neutral | $592.55M | ― | -28.73% | ― | 189.31% | 51.03% | |
46 Neutral | $600.54M | ― | -343.83% | ― | 387.20% | 21.00% | |
45 Neutral | $570.24M | ― | -150.50% | ― | ― | -18.75% | |
45 Neutral | $738.73M | ― | -69.21% | ― | -13.76% | 57.73% |
On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.
On March 4, 2025, Dianthus Therapeutics announced the resignation of Tomas Kiselak from its Board of Directors, which was not due to any disagreements with the company. The same day, Sujay Kango was appointed as a Class II director and a member of the Compensation Committee, receiving stock options and cash compensation in line with the company’s policies.